Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carfilzomib + cyclophosphamide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Onyx Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A triplet regimen combining carfilzomib (a second-generation proteasome inhibitor), cyclophosphamide (an alkylating agent), and dexamethasone (a corticosteroid) used in the treatment of multiple myeloma. This combination is administered in 28-day cycles and has shown efficacy in both newly diagnosed and relapsed/refractory multiple myeloma patients, including those with high-risk cytogenetics.
- Brand names
- KyprolisCytoxanDecadron
- Other names
- CarCyDex
02
Targets
PSMB5 (Proteasome subunit beta Type-5)DNAGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on carfilzomib + cyclophosphamide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carfilzomib + cyclophosphamide + dexamethasone.